- Conditions
- Covid19, Coronavirus, SARS-CoV 2
- Interventions
- QuadraMune(TM)
- Dietary Supplement
- Lead sponsor
- Therapeutic Solutions International
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Oceanside, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Participants
- Interventions
- REGN10933 + REGN10987, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Day and older
- Enrollment
- 3,303 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 132
- States / cities
- Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more
- Conditions
- Covid19
- Interventions
- Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday
- Behavioral
- Lead sponsor
- National Bureau of Economic Research, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 820 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Covid19
- Interventions
- AntiCov-220, AntiCov-220 (placebo)
- Drug
- Lead sponsor
- Nguyen Thi Trieu, MD
- Individual
- Eligibility
- 16 Years to 82 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Covid19
- Interventions
- VXA-CoV2-1
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Coronavirus Infections, Healthcare Associated Infection
- Interventions
- Inhaled nitric oxide gas
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Covid19
- Interventions
- Apixaban 2.5 MG, Placebo
- Drug
- Lead sponsor
- Thomas L. Ortel
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 121
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 101 more
- Conditions
- COVID-19 Disease
- Interventions
- Apilimod Dimesylate Capsule, Placebo
- Drug · Other
- Lead sponsor
- OrphAI Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- COVID, Coronavirus Infection
- Interventions
- Chloroquine, Placebo oral tablet
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COVID-19 Prevention
- Interventions
- Q-Griffithsin 3.0, Q-Griffithsin 6.0
- Drug
- Lead sponsor
- Kenneth Palmer
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- COVID-19
- Interventions
- VYD2311-SD, VYD2311-MD, Placebo
- Drug
- Lead sponsor
- Invivyd, Inc.
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 1,770 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 20
- States / cities
- Long Beach, California • San Diego, California • Orlando, Florida + 17 more
- Conditions
- COVID-19
- Interventions
- Dapsone 85 mg PO BID, Placebo 85 mg PO BID
- Drug
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • High Point, North Carolina • Philadelphia, Pennsylvania + 2 more
- Conditions
- COVID-19
- Interventions
- Hydroxychloroquine
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- COVID-19, Corona Virus Infection
- Interventions
- Hydroxychloroquine, Placebo oral tablet
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
- Interventions
- Hydroxychloroquine Sulfate, Ascorbic Acid
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 8
- States / cities
- Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
- Conditions
- HIV-1-infection, Hypertension
- Interventions
- EXTRA-CVD Virtual Care
- Other
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Cleveland, Ohio
- Conditions
- SARS-CoV-2, COVID-19
- Interventions
- EVUSHELD
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 4,232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- SARS-CoV Infection, COVID-19
- Interventions
- Mitoquinone/mitoquinol mesylate, Placebo
- Drug · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Covid19
- Interventions
- Nasal lavage
- Other
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- COVID-19
- Interventions
- ADG20, Placebo
- Drug
- Lead sponsor
- Invivyd, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 2,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 60 more
- Conditions
- COVID -19, COVID-19 (Prevention)
- Interventions
- MDX2301, Normal Saline
- Biological
- Lead sponsor
- ModeX Therapeutics, An OPKO Health Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • Austin, Texas
- Conditions
- Chronic Lymphocytic Leukemia, COVID-19 Infection
- Interventions
- Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- Procedure · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California